Top

Published in:

01-02-2005 | Article

Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes

Authors: Y. H. Hamid, C. S. Rose, S. A. Urhammer, C. Glümer, R. Nolsøe, O. P. Kristiansen, T. Mandrup-Poulsen, K. Borch-Johnsen, T. Jorgensen, T. Hansen, O. Pedersen

Published in: Diabetologia | Issue 2/2005

Abstract

Aims/hypothesis

The cytokine interleukin 6 (IL-6) is an essential regulator of the acute phase response associated with insulin-resistant states including type 2 diabetes and obesity. Three polymorphisms at positions −597, −572, and −174 of the IL6 promoter have been reported to influence IL6 transcription. The aim of this study was to investigate whether the IL6 promoter polymorphisms were associated with features of the WHO-defined metabolic syndrome and related quantitative traits in 7,553 Caucasian Danes.

Methods

Using analysis of PCR-generated primer extension products by mass spectrometry we examined −597 G/A, −572 G/C, and −174 G/C IL6 variants in the population-based Inter99 study cohort of middle-aged people (n=6,164) and in a group of type 2 diabetic patients (n=1,389).

Results

The −174 G/C and −597 G/A polymorphisms were in strong linkage disequilibrium (R ²=0.95). In the Inter99 cohort the −174 G-allele was associated with insulin resistance (p<0.02) and dyslipidaemia (p<0.007) whereas the C-allele of the −572 polymorphism was associated with increased serum insulin release during an OGTT (p<0.0005). Composite genotype or haplotype analyses of all 3 IL6 promoter variants showed associations with type 2 diabetes (p<0.002), obesity (p<0.02), and the metabolic syndrome (p<0.01).

Conclusions

The present studies suggest that single-nucleotide polymorphisms and composite genotypes or haplotypes of the IL6 promoter may be associated with several features of the metabolic syndrome in Caucasians.

Akira S, Taga T, Kishimoto T (1993) Interleukin-6 in biology and medicine. Adv Immunol 54:1–78

Mohamed-Ali V, Goodrick S, Rawesh A et al (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha in vivo. J Clin Endocrinol Metab 82:4196–4200CrossRefPubMed

Steensberg A, Febbraio MA, Osada T et al (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537:633–639PubMed

Mohamed-Ali V, Flower L, Sethi J et al (2001) Beta-adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 86:5864–5869CrossRef

Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP (1998) The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128:127–137PubMed

Boulanger MJ, Chow DC, Brevnova EE, Garcia KC (2003) Hexameric structure and assembly of the interleukin-6/IL-6 {alpha}-receptor/gp130 complex. Science 300:2101–2104CrossRef

Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 102:42–47PubMed

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751PubMed

Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–1292CrossRefPubMed

10.

Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417PubMed

11.

Pickup JC, Chusney GD, Thomas SM, Burt D (2000) Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in Type-2 diabetes. Life Sci 67:291–300CrossRefPubMed

12.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing Type-2 diabetes mellitus. JAMA 286:327–334CrossRefPubMed

13.

Tsigos C, Papanicolaou DA, Kyrou I, Raptis SA, Chrousos GP (1999) Dose-dependent effects of recombinant human interleukin-6 on the pituitary–testicular axis. J Interferon Cytokine Res 19:1271–1276CrossRef

14.

Fishman D, Faulds G, Jeffery R et al (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376PubMed

15.

Bonafe M, Olivieri F, Cavallone L et al (2001) A gender–dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 31:2357–2361CrossRef

16.

Olivieri F, Bonafe M, Cavallone L et al (2002) The −174 C/G locus affects in vitro/in vivo IL-6 production during aging. Exp Gerontol 37:309–314CrossRef

17.

Vozarova B, Fernandez-Real JM, Knowler WC et al (2003) The interleukin-6 (−174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in native Americans and Caucasians. Hum Genet 112:409–413PubMed

18.

Berthier MT, Paradis AM, Tchernof A et al (2003) The interleukin 6 −174G/C polymorphism is associated with indices of obesity in men. J Hum Genet 48:14–19CrossRef

19.

Wernstedt I, Eriksson AL, Berndtsson A et al (2004) A common polymorphism in the interleukin-6 gene promoter is associated with overweight. Int J Obes Related Metab Disord 28:1272–1279CrossRef

20.

Fernandez-Real JM, Broch M, Vendrell J et al (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517–520PubMed

21.

Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W (2000) Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 85:1334–1339CrossRef

22.

Kitamura A, Hasegawa G, Obayashi H et al (2002) Interleukin-6 polymorphism (−634C/G) in the promotor region and the progression of diabetic nephropathy in Type-2 diabetes. Diabet Med 19:1000–1005CrossRef

23.

Villuendas G, San Millan JL, Sancho J, Escobar-Morreale HF (2002) The −597 G→A and −174 G→C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 87:1134–1141CrossRef

24.

Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL (2003) Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88:255–259CrossRef

25.

Muller-Steinhardt M (2004) Cooperative influence of the interleukin-6 promoter polymorphisms −597, −572 and −174 on long-term kidney allograft survival. Am J Transplant 4:402–406CrossRef

26.

Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O’Keefe GE (2003) Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 20:218–223CrossRef

27.

Terry CF, Loukaci V, Green FR (2000) Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138–18144

28.

Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1). Eur J Cardiovasc Prev Rehabil 10:377–386CrossRef

29.

WHO Study Group (1999) Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva

30.

Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215PubMed

31.

Buetow KH, Edmonson M, MacDonald R et al (2001) High-throughput development and characterization of a genomewide collection of gene-based single-nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 98:581–584CrossRefPubMed

32.

Fernandez-Real JM, Vayreda M, Richart C et al (2001) Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154–1159CrossRefPubMed

33.

Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM (2003) Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 13:674–682CrossRef

34.

Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399PubMed

35.

Van Hall G, Steensberg A, Sacchetti M et al (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005–3010CrossRefPubMed

36.

Wallenius K, Jansson JO, Wallenius V (2003) The therapeutic potential of interleukin-6 in treating obesity. Expert Opin Biol Ther 3:1061–1070CrossRef

37.

Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79CrossRefPubMed

38.

Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA (2004) Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 287:E182–E187CrossRefPubMed

39.

Stith RD, Luo J (1994) Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44:210–215PubMed

40.

Nonogaki K, Fuller GM, Fuentes NL et al (1995) Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136:2143–2149CrossRefPubMed

41.

Wolford JK, Gruber JD, Ossowski VM, et al (2003) A C-reactive protein promoter polymorphism is associated with Type-2 diabetes mellitus in Pima Indians. Mol Genet Metab 78:136–144CrossRef

42.

Kubaszek A, Pihlajamaki J, Punnonen K, Karhapää P, Vauhkonen I, Laakso M (2003) The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 52:558–561

Title: Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes
Authors: Y. H. Hamid
C. S. Rose
S. A. Urhammer
C. Glümer
R. Nolsøe
O. P. Kristiansen
T. Mandrup-Poulsen
K. Borch-Johnsen
T. Jorgensen
T. Hansen
O. Pedersen
Publication date: 01-02-2005
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 2/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-004-1623-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2005

Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA1c

Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the ‘Darwin study’

Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells

Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients

The hyperbolic law—a 25-year perspective

Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials